Copy Link Print Information

T0070907

45 Cited Publications
Revisión del cliente

Based on 45 publication(s) in Google Scholar

T0070907 is a potent PPARγ antagonist with a Ki of 1 nM.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.94%
  • No. CAS: 313516-66-4
  • Fòrmula: C12H8ClN3O3
  • Peso molecular:277.66
  • Almacenamiento:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • T0070907 Chemical Structure
    T0070907 Chemical Structure
  • Experimental Validation Results for T0070907
  • Experimental Validation Results for T0070907
  • Experimental Validation Results for T0070907
  • Experimental Validation Results for T0070907
  • Experimental Validation Results for T0070907
  • Experimental Validation Results for T0070907
No. CAS: 313516-66-4
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of T0070907:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) T0070907

More
Customer Validation & Images
Cell Proliferation/Viability AssayRT-PCRIn Vivo Efficacy StudyWBFlow Cytometry
  • RT-PCR
  • WB
  • Flow Cytometry
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay

Ver todos los productos específicos de isoformas PPAR

More
Keywords
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • T0070907 Chemical Structure
    T0070907 Chemical Structure
    1/16
  • 1/16

    T0070907 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 10;16(1):8215. [Abstract]

    Customer Validation
     NECTIN4 mRNA levels in RT112 cells treated with 1 μM Rosiglitazone and T0070907 (T007) for 72 h.

  • 1/16

    T0070907 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 10;16(1):8215. [Abstract]

    Customer Validation
     T0070907 (0.5-2.5 μM; 72 h). Western blot for NECTIN4 and HPGD in RT112 cells treated with T0070907, Rosiglitazone, and Pioglitazone at indicated concentrations for 72 h.

  • 1/16

    T0070907 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 10;16(1):8215. [Abstract]

    Customer Validation
     NECTIN4 surface staining in RT112 cells treated with 1 μM Rosiglitazone and T0070907 for 72 h.

  • 1/16

    T0070907 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 11:e08957. [Abstract]

    Customer Validation
     T0070907 (10 µM; 1 µL per side; microinjected into the mPFC). The social interaction ratio of mice from control, SUS-vehicle, SUS-vehicle-pioglitazone, SUS-T0070907-pioglitazone groups.

  • 1/16

    T0070907 purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2024 Apr:102:105079. [Abstract]

    Customer Validation
     T0070907 (0-15 μM; 24 h). Viability of HepG2 cells treated with 400 μM PA and indicated concentrations of T0070907 for 24 h.

  • 1/16

    T0070907 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005. [Abstract]

    Customer Validation
     HT22 cells were pretreated with the indicated inhibitors (CDDO (Bardoxolone, HY-14909); T0070907 (HY-13202); Troglitazone (HY-50935 ); TPCA-1 (HY-10074); JAKi; STAT3i; AV-412 (HY-10346); and MK2206 (HY-10358)) and then treated with T/Z, T/S/Z, T/C/Z for 9 h or Glutamate, Erastin (T: 20 ng/ml; Z: 50 μM; S: 20 nM; C: 1 μg/ml; Glutamate: 50 mM; Erastin 10 μM) for 12 h. Cell viability was measured by CellTiterGlo assay.

  • T0070907